Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 25 entries
Sorted by: Best Match Show Resources per page
Primary small cell cancer of the esophagus: understanding treatment outcomes.

Journal of thoracic disease

Semenkovich TR, Meyers BF.
PMID: 29849193
J Thorac Dis. 2018 Apr;10:S1025-S1028. doi: 10.21037/jtd.2018.03.176.

No abstract available.

Cite
Semenkovich TR, Meyers BF. Primary small cell cancer of the esophagus: understanding treatment outcomes. J Thorac Dis. 2018;10:S1025-S1028doi: 10.21037/jtd.2018.03.176.
Semenkovich, T. R., & Meyers, B. F. (2018). Primary small cell cancer of the esophagus: understanding treatment outcomes. Journal of thoracic disease, 10S1025-S1028. https://doi.org/10.21037/jtd.2018.03.176
Semenkovich, Tara R, and Meyers, Bryan F. "Primary small cell cancer of the esophagus: understanding treatment outcomes." Journal of thoracic disease vol. 10 (2018): S1025-S1028. doi: https://doi.org/10.21037/jtd.2018.03.176
Semenkovich TR, Meyers BF. Primary small cell cancer of the esophagus: understanding treatment outcomes. J Thorac Dis. 2018 Apr;10:S1025-S1028. doi: 10.21037/jtd.2018.03.176. PMID: 29849193; PMCID: PMC5949429.
Copy Download .nbib Format: NLM
Comprehensive Assessment of Current Management Strategies for Patients With Diabetes and Chronic Limb-Threatening Ischemia.

Clinical diabetes : a publication of the American Diabetes Association

Tay S, Abdulnabi S, Saffaf O, Harroun N, Yang C, Semenkovich CF, Zayed MA.
PMID: 34866779
Clin Diabetes. 2021 Oct;39(4):358-388. doi: 10.2337/cd21-0019.

Chronic limb-threatening ischemia (CLTI) is the most severe form of peripheral artery disease. It is estimated that 60% of all nontraumatic lower-extremity amputations performed annually in the United States are in patients with diabetes and CLTI. The consequences of...

Cite
Tay S, Abdulnabi S, Saffaf O, et al. Comprehensive Assessment of Current Management Strategies for Patients With Diabetes and Chronic Limb-Threatening Ischemia. Clin Diabetes. 2021;39(4):358-388doi: 10.2337/cd21-0019.
Tay, S., Abdulnabi, S., Saffaf, O., Harroun, N., Yang, C., Semenkovich, C. F., & Zayed, M. A. (2021). Comprehensive Assessment of Current Management Strategies for Patients With Diabetes and Chronic Limb-Threatening Ischemia. Clinical diabetes : a publication of the American Diabetes Association, 39(4), 358-388. https://doi.org/10.2337/cd21-0019
Tay, Shirli, et al. "Comprehensive Assessment of Current Management Strategies for Patients With Diabetes and Chronic Limb-Threatening Ischemia." Clinical diabetes : a publication of the American Diabetes Association vol. 39,4 (2021): 358-388. doi: https://doi.org/10.2337/cd21-0019
Tay S, Abdulnabi S, Saffaf O, Harroun N, Yang C, Semenkovich CF, Zayed MA. Comprehensive Assessment of Current Management Strategies for Patients With Diabetes and Chronic Limb-Threatening Ischemia. Clin Diabetes. 2021 Oct;39(4):358-388. doi: 10.2337/cd21-0019. PMID: 34866779; PMCID: PMC8603325.
Copy Download .nbib Format: NLM
Comprehensive Assessment of Current Management Strategies for Patients With Diabetes and Chronic Limb-Threatening Ischemia.

Clinical diabetes : a publication of the American Diabetes Association

Tay S, Abdulnabi S, Saffaf O, Harroun N, Yang C, Semenkovich CF, Zayed MA.
PMID: 34866779
Clin Diabetes. 2021 Oct;39(4):358-388. doi: 10.2337/cd21-0019.

Chronic limb-threatening ischemia (CLTI) is the most severe form of peripheral artery disease. It is estimated that 60% of all nontraumatic lower-extremity amputations performed annually in the United States are in patients with diabetes and CLTI. The consequences of...

Cite
Tay S, Abdulnabi S, Saffaf O, et al. Comprehensive Assessment of Current Management Strategies for Patients With Diabetes and Chronic Limb-Threatening Ischemia. Clin Diabetes. 2021;39(4):358-388doi: 10.2337/cd21-0019.
Tay, S., Abdulnabi, S., Saffaf, O., Harroun, N., Yang, C., Semenkovich, C. F., & Zayed, M. A. (2021). Comprehensive Assessment of Current Management Strategies for Patients With Diabetes and Chronic Limb-Threatening Ischemia. Clinical diabetes : a publication of the American Diabetes Association, 39(4), 358-388. https://doi.org/10.2337/cd21-0019
Tay, Shirli, et al. "Comprehensive Assessment of Current Management Strategies for Patients With Diabetes and Chronic Limb-Threatening Ischemia." Clinical diabetes : a publication of the American Diabetes Association vol. 39,4 (2021): 358-388. doi: https://doi.org/10.2337/cd21-0019
Tay S, Abdulnabi S, Saffaf O, Harroun N, Yang C, Semenkovich CF, Zayed MA. Comprehensive Assessment of Current Management Strategies for Patients With Diabetes and Chronic Limb-Threatening Ischemia. Clin Diabetes. 2021 Oct;39(4):358-388. doi: 10.2337/cd21-0019. PMID: 34866779; PMCID: PMC8603325.
Copy Download .nbib Format: NLM
The role of small or single-institution prospective studies in thoracic research.

Journal of thoracic disease

Semenkovich TR, Frye CC, Harrison MS, Subramanian M, Kozower BD, Meyers BF, Puri V.
PMID: 31032073
J Thorac Dis. 2019 Mar;11:S555-S561. doi: 10.21037/jtd.2019.01.18.

Interventional studies are designed specifically to test the impact of a treatment or management strategy on an outcome of interest. In this article, we will highlight two viewpoints regarding the role of small or single-institution prospective interventional studies within...

Cite
Semenkovich TR, Frye CC, Harrison MS, et al. The role of small or single-institution prospective studies in thoracic research. J Thorac Dis. 2019;11:S555-S561doi: 10.21037/jtd.2019.01.18.
Semenkovich, T. R., Frye, C. C., Harrison, M. S., Subramanian, M., Kozower, B. D., Meyers, B. F., & Puri, V. (2019). The role of small or single-institution prospective studies in thoracic research. Journal of thoracic disease, 11S555-S561. https://doi.org/10.21037/jtd.2019.01.18
Semenkovich, Tara R, et al. "The role of small or single-institution prospective studies in thoracic research." Journal of thoracic disease vol. 11 (2019): S555-S561. doi: https://doi.org/10.21037/jtd.2019.01.18
Semenkovich TR, Frye CC, Harrison MS, Subramanian M, Kozower BD, Meyers BF, Puri V. The role of small or single-institution prospective studies in thoracic research. J Thorac Dis. 2019 Mar;11:S555-S561. doi: 10.21037/jtd.2019.01.18. PMID: 31032073; PMCID: PMC6465428.
Copy Download .nbib Format: NLM
Prevalence of elevated serum fatty acid synthase in chronic limb-threatening ischemia.

Scientific reports

Tay S, De Silva GS, Engel CM, Harroun N, Penrose AS, Desai KA, Yan Y, Semenkovich CF, Zayed MA.
PMID: 34588500
Sci Rep. 2021 Sep 29;11(1):19272. doi: 10.1038/s41598-021-98479-7.

There are currently no serum-based evaluations that can corroborate the severity of peripheral artery disease (PAD). In this cross-sectional study, we assessed the prevalence of elevated serum fatty acid synthase (cFAS) in patients with chronic limb-threatening ischemia (CLTI) and...

Cite
Tay S, De Silva GS, Engel CM, et al. Prevalence of elevated serum fatty acid synthase in chronic limb-threatening ischemia. Sci Rep. 2021;11(1):19272doi: 10.1038/s41598-021-98479-7.
Tay, S., De Silva, G. S., Engel, C. M., Harroun, N., Penrose, A. S., Desai, K. A., Yan, Y., Semenkovich, C. F., & Zayed, M. A. (2021). Prevalence of elevated serum fatty acid synthase in chronic limb-threatening ischemia. Scientific reports, 11(1), 19272. https://doi.org/10.1038/s41598-021-98479-7
Tay, Shirli, et al. "Prevalence of elevated serum fatty acid synthase in chronic limb-threatening ischemia." Scientific reports vol. 11,1 (2021): 19272. doi: https://doi.org/10.1038/s41598-021-98479-7
Tay S, De Silva GS, Engel CM, Harroun N, Penrose AS, Desai KA, Yan Y, Semenkovich CF, Zayed MA. Prevalence of elevated serum fatty acid synthase in chronic limb-threatening ischemia. Sci Rep. 2021 Sep 29;11(1):19272. doi: 10.1038/s41598-021-98479-7. PMID: 34588500; PMCID: PMC8481229.
Copy Download .nbib Format: NLM
Fenofibrate Reduces the Severity of Neuroretinopathy in a Type 2 Model of Diabetes without Inducing Peroxisome Proliferator-Activated Receptor Alpha-Dependent Retinal Gene Expression.

Journal of clinical medicine

Enright JM, Zhang S, Thebeau C, Siebert E, Jin A, Gadiraju V, Zhang X, Chen S, Semenkovich CF, Rajagopal R.
PMID: 33396512
J Clin Med. 2020 Dec 31;10(1). doi: 10.3390/jcm10010126.

Fenofibrate slows the progression of clinical diabetic retinopathy (DR), but its mechanism of action in the retina remains unclear. Fenofibrate is a known agonist of peroxisome proliferator-activated receptor alpha (PPARα), a transcription factor critical for regulating metabolism, inflammation and...

Cite
Enright JM, Zhang S, Thebeau C, et al. Fenofibrate Reduces the Severity of Neuroretinopathy in a Type 2 Model of Diabetes without Inducing Peroxisome Proliferator-Activated Receptor Alpha-Dependent Retinal Gene Expression. J Clin Med. 2020;10(1)doi: 10.3390/jcm10010126.
Enright, J. M., Zhang, S., Thebeau, C., Siebert, E., Jin, A., Gadiraju, V., Zhang, X., Chen, S., Semenkovich, C. F., & Rajagopal, R. (2020). Fenofibrate Reduces the Severity of Neuroretinopathy in a Type 2 Model of Diabetes without Inducing Peroxisome Proliferator-Activated Receptor Alpha-Dependent Retinal Gene Expression. Journal of clinical medicine, 10(1), . https://doi.org/10.3390/jcm10010126
Enright, Jennifer M, et al. "Fenofibrate Reduces the Severity of Neuroretinopathy in a Type 2 Model of Diabetes without Inducing Peroxisome Proliferator-Activated Receptor Alpha-Dependent Retinal Gene Expression." Journal of clinical medicine vol. 10,1 (2020). doi: https://doi.org/10.3390/jcm10010126
Enright JM, Zhang S, Thebeau C, Siebert E, Jin A, Gadiraju V, Zhang X, Chen S, Semenkovich CF, Rajagopal R. Fenofibrate Reduces the Severity of Neuroretinopathy in a Type 2 Model of Diabetes without Inducing Peroxisome Proliferator-Activated Receptor Alpha-Dependent Retinal Gene Expression. J Clin Med. 2020 Dec 31;10(1). doi: 10.3390/jcm10010126. PMID: 33396512; PMCID: PMC7794763.
Copy Download .nbib Format: NLM
Endothelial ether lipids link the vasculature to blood pressure, behavior, and neurodegeneration.

Journal of lipid research

Spears LD, Adak S, Dong G, Wei X, Spyropoulos G, Zhang Q, Yin L, Feng C, Hu D, Lodhi IJ, Hsu FF, Rajagopal R, Noguchi KK, Halabi CM, Brier L, Bice AR, Lananna BV, Musiek ES, Avraham O, Cavalli V, Holth JK, Holtzman DM, Wozniak DF, Culver JP, Semenkovich CF.
PMID: 33894211
J Lipid Res. 2021;62:100079. doi: 10.1016/j.jlr.2021.100079. Epub 2021 Apr 21.

Vascular disease contributes to neurodegeneration, which is associated with decreased blood pressure in older humans. Plasmalogens, ether phospholipids produced by peroxisomes, are decreased in Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders. However, the mechanistic links between ether phospholipids,...

Cite
Spears LD, Adak S, Dong G, et al. Endothelial ether lipids link the vasculature to blood pressure, behavior, and neurodegeneration. J Lipid Res. 2021;62:100079doi: 10.1016/j.jlr.2021.100079.
Spears, L. D., Adak, S., Dong, G., Wei, X., Spyropoulos, G., Zhang, Q., Yin, L., Feng, C., Hu, D., Lodhi, I. J., Hsu, F. F., Rajagopal, R., Noguchi, K. K., Halabi, C. M., Brier, L., Bice, A. R., Lananna, B. V., Musiek, E. S., Avraham, O., Cavalli, V., Holth, J. K., Holtzman, D. M., Wozniak, D. F., Culver, J. P., & Semenkovich, C. F. (2021). Endothelial ether lipids link the vasculature to blood pressure, behavior, and neurodegeneration. Journal of lipid research, 62100079. https://doi.org/10.1016/j.jlr.2021.100079
Spears, Larry D, et al. "Endothelial ether lipids link the vasculature to blood pressure, behavior, and neurodegeneration." Journal of lipid research vol. 62 (2021): 100079. doi: https://doi.org/10.1016/j.jlr.2021.100079
Spears LD, Adak S, Dong G, Wei X, Spyropoulos G, Zhang Q, Yin L, Feng C, Hu D, Lodhi IJ, Hsu FF, Rajagopal R, Noguchi KK, Halabi CM, Brier L, Bice AR, Lananna BV, Musiek ES, Avraham O, Cavalli V, Holth JK, Holtzman DM, Wozniak DF, Culver JP, Semenkovich CF. Endothelial ether lipids link the vasculature to blood pressure, behavior, and neurodegeneration. J Lipid Res. 2021;62:100079. doi: 10.1016/j.jlr.2021.100079. Epub 2021 Apr 21. PMID: 33894211; PMCID: PMC8144742.
Copy Download .nbib Format: NLM
Development and initial validation of the diabetes family conflict scale (revised)-short form in a racially and income diverse sample.

Pediatric diabetes

Semenkovich KA, Berlin KS, Ankney RL, Keenan ME, L Cook J, Klages KL, Banks GG, Rybak TM, Alemzadeh R, Eddington AR.
PMID: 33476074
Pediatr Diabetes. 2021 May;22(3):529-539. doi: 10.1111/pedi.13182. Epub 2021 Feb 02.

OBJECTIVE: The purpose of the study was to develop a short form of the revised diabetes family conflict scale (DFCS) in a racially and income diverse sample while retaining strong psychometric properties.METHODS: One seventy nine youth with type 1...

Cite
Semenkovich KA, Berlin KS, Ankney RL, et al. Development and initial validation of the diabetes family conflict scale (revised)-short form in a racially and income diverse sample. Pediatr Diabetes. 2021;22(3):529-539doi: 10.1111/pedi.13182.
Semenkovich, K. A., Berlin, K. S., Ankney, R. L., Keenan, M. E., L Cook, J., Klages, K. L., Banks, G. G., Rybak, T. M., Alemzadeh, R., & Eddington, A. R. (2021). Development and initial validation of the diabetes family conflict scale (revised)-short form in a racially and income diverse sample. Pediatric diabetes, 22(3), 529-539. https://doi.org/10.1111/pedi.13182
Semenkovich, Katherine A, et al. "Development and initial validation of the diabetes family conflict scale (revised)-short form in a racially and income diverse sample." Pediatric diabetes vol. 22,3 (2021): 529-539. doi: https://doi.org/10.1111/pedi.13182
Semenkovich KA, Berlin KS, Ankney RL, Keenan ME, L Cook J, Klages KL, Banks GG, Rybak TM, Alemzadeh R, Eddington AR. Development and initial validation of the diabetes family conflict scale (revised)-short form in a racially and income diverse sample. Pediatr Diabetes. 2021 May;22(3):529-539. doi: 10.1111/pedi.13182. Epub 2021 Feb 02. PMID: 33476074.
Copy Download .nbib Format: NLM
Examining Risk Factors of Health-Related Quality of Life Impairments Among Adolescents with Inflammatory Bowel Disease.

Behavioral medicine (Washington, D.C.)

Klages KL, Berlin KS, Cook JL, Keenan ME, Semenkovich K, Banks GG, Rybak TM, Ankney RL, Decker KM, Whitworth JR, Corkins MR.
PMID: 34048329
Behav Med. 2021 Apr-Jun;47(2):140-150. doi: 10.1080/08964289.2019.1676193. Epub 2020 Jun 17.

Inflammatory Bowel Disease (IBD) is a chronic, costly, and burdensome disease that is typically diagnosed during adolescence. Despite the use of effective treatments, rates of relapse and intestinal inflammation remain high and put patients at risk for long term...

Cite
Klages KL, Berlin KS, Cook JL, et al. Examining Risk Factors of Health-Related Quality of Life Impairments Among Adolescents with Inflammatory Bowel Disease. Behav Med. 2020;47(2):140-150doi: 10.1080/08964289.2019.1676193.
Klages, K. L., Berlin, K. S., Cook, J. L., Keenan, M. E., Semenkovich, K., Banks, G. G., Rybak, T. M., Ankney, R. L., Decker, K. M., Whitworth, J. R., & Corkins, M. R. (2021). Examining Risk Factors of Health-Related Quality of Life Impairments Among Adolescents with Inflammatory Bowel Disease. Behavioral medicine (Washington, D.C.), 47(2), 140-150. https://doi.org/10.1080/08964289.2019.1676193
Klages, Kimberly L, et al. "Examining Risk Factors of Health-Related Quality of Life Impairments Among Adolescents with Inflammatory Bowel Disease." Behavioral medicine (Washington, D.C.) vol. 47,2 (2021): 140-150. doi: https://doi.org/10.1080/08964289.2019.1676193
Klages KL, Berlin KS, Cook JL, Keenan ME, Semenkovich K, Banks GG, Rybak TM, Ankney RL, Decker KM, Whitworth JR, Corkins MR. Examining Risk Factors of Health-Related Quality of Life Impairments Among Adolescents with Inflammatory Bowel Disease. Behav Med. 2021 Apr-Jun;47(2):140-150. doi: 10.1080/08964289.2019.1676193. Epub 2020 Jun 17. PMID: 34048329.
Copy Download .nbib Format: NLM
FASN-dependent de novo lipogenesis is required for brain development.

Proceedings of the National Academy of Sciences of the United States of America

Gonzalez-Bohorquez D, Gallego López IM, Jaeger BN, Pfammatter S, Bowers M, Semenkovich CF, Jessberger S.
PMID: 34996870
Proc Natl Acad Sci U S A. 2022 Jan 11;119(2). doi: 10.1073/pnas.2112040119.

Fate and behavior of neural progenitor cells are tightly regulated during mammalian brain development. Metabolic pathways, such as glycolysis and oxidative phosphorylation, that are required for supplying energy and providing molecular building blocks to generate cells govern progenitor function....

Cite
Gonzalez-Bohorquez D, Gallego López IM, Jaeger BN, et al. FASN-dependent de novo lipogenesis is required for brain development. Proc Natl Acad Sci U S A. 2022;119(2)doi: 10.1073/pnas.2112040119.
Gonzalez-Bohorquez, D., Gallego López, I. M., Jaeger, B. N., Pfammatter, S., Bowers, M., Semenkovich, C. F., & Jessberger, S. (2022). FASN-dependent de novo lipogenesis is required for brain development. Proceedings of the National Academy of Sciences of the United States of America, 119(2), . https://doi.org/10.1073/pnas.2112040119
Gonzalez-Bohorquez, Daniel, et al. "FASN-dependent de novo lipogenesis is required for brain development." Proceedings of the National Academy of Sciences of the United States of America vol. 119,2 (2022). doi: https://doi.org/10.1073/pnas.2112040119
Gonzalez-Bohorquez D, Gallego López IM, Jaeger BN, Pfammatter S, Bowers M, Semenkovich CF, Jessberger S. FASN-dependent de novo lipogenesis is required for brain development. Proc Natl Acad Sci U S A. 2022 Jan 11;119(2). doi: 10.1073/pnas.2112040119. PMID: 34996870.
Copy Download .nbib Format: NLM
Understanding the impact of neoadjuvant chemoradiation on health-related quality of life in esophageal cancer.

Video-assisted thoracic surgery

Semenkovich TR, Meyers BF.
PMID: 30221248
Video Assist Thorac Surg. 2018 Jul;3. doi: 10.21037/vats.2018.06.01. Epub 2018 Jul 03.

No abstract available.

Cite
Semenkovich TR, Meyers BF. Understanding the impact of neoadjuvant chemoradiation on health-related quality of life in esophageal cancer. Video Assist Thorac Surg. 2018;3doi: 10.21037/vats.2018.06.01.
Semenkovich, T. R., & Meyers, B. F. (2018). Understanding the impact of neoadjuvant chemoradiation on health-related quality of life in esophageal cancer. Video-assisted thoracic surgery, 3. https://doi.org/10.21037/vats.2018.06.01
Semenkovich, Tara R, and Meyers, Bryan F. "Understanding the impact of neoadjuvant chemoradiation on health-related quality of life in esophageal cancer." Video-assisted thoracic surgery vol. 3 (2018). doi: https://doi.org/10.21037/vats.2018.06.01
Semenkovich TR, Meyers BF. Understanding the impact of neoadjuvant chemoradiation on health-related quality of life in esophageal cancer. Video Assist Thorac Surg. 2018 Jul;3. doi: 10.21037/vats.2018.06.01. Epub 2018 Jul 03. PMID: 30221248; PMCID: PMC6135084.
Copy Download .nbib Format: NLM
Low dose chloroquine decreases insulin resistance in human metabolic syndrome but does not reduce carotid intima-media thickness.

Diabetology & metabolic syndrome

McGill JB, Johnson M, Hurst S, Cade WT, Yarasheski KE, Ostlund RE, Schechtman KB, Razani B, Kastan MB, McClain DA, de Las Fuentes L, Davila-Roman VG, Ory DS, Wickline SA, Semenkovich CF.
PMID: 31384309
Diabetol Metab Syndr. 2019 Jul 29;11:61. doi: 10.1186/s13098-019-0456-4. eCollection 2019.

BACKGROUND: Metabolic syndrome, an obesity-related condition associated with insulin resistance and low-grade inflammation, leads to diabetes, cardiovascular diseases, cancer, osteoarthritis, and other disorders. Optimal therapy is unknown. The antimalarial drug chloroquine activates the kinase ataxia telangiectasia mutated (ATM), improves...

Cite
McGill JB, Johnson M, Hurst S, et al. Low dose chloroquine decreases insulin resistance in human metabolic syndrome but does not reduce carotid intima-media thickness. Diabetol Metab Syndr. 2019;11:61doi: 10.1186/s13098-019-0456-4.
McGill, J. B., Johnson, M., Hurst, S., Cade, W. T., Yarasheski, K. E., Ostlund, R. E., Schechtman, K. B., Razani, B., Kastan, M. B., McClain, D. A., de Las Fuentes, L., Davila-Roman, V. G., Ory, D. S., Wickline, S. A., & Semenkovich, C. F. (2019). Low dose chloroquine decreases insulin resistance in human metabolic syndrome but does not reduce carotid intima-media thickness. Diabetology & metabolic syndrome, 1161. https://doi.org/10.1186/s13098-019-0456-4
McGill, Janet B, et al. "Low dose chloroquine decreases insulin resistance in human metabolic syndrome but does not reduce carotid intima-media thickness." Diabetology & metabolic syndrome vol. 11 (2019): 61. doi: https://doi.org/10.1186/s13098-019-0456-4
McGill JB, Johnson M, Hurst S, Cade WT, Yarasheski KE, Ostlund RE, Schechtman KB, Razani B, Kastan MB, McClain DA, de Las Fuentes L, Davila-Roman VG, Ory DS, Wickline SA, Semenkovich CF. Low dose chloroquine decreases insulin resistance in human metabolic syndrome but does not reduce carotid intima-media thickness. Diabetol Metab Syndr. 2019 Jul 29;11:61. doi: 10.1186/s13098-019-0456-4. eCollection 2019. PMID: 31384309; PMCID: PMC6664523.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 25 entries